Welcome to our dedicated page for Theravance Bioph SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theravance Biopharma, Inc. (NASDAQ: TBPH) SEC filings page aggregates the company’s regulatory disclosures, allowing investors to review how this biopharmaceutical issuer reports its financial condition, clinical milestones, and material events. Theravance Biopharma is incorporated in the Cayman Islands and files with the U.S. Securities and Exchange Commission under Commission File Number 001-36033. Its current reports on Form 8-K provide insight into quarterly financial results, strategic transactions, patent settlements, and key clinical and regulatory developments.
Current reports (Form 8-K) for Theravance Biopharma include items on results of operations and financial condition, where the company furnishes press releases and slide decks summarizing quarterly revenue, collaboration income from YUPELRI (revefenacin) inhalation solution, research and development spending, and cash position. Other 8-K filings describe clinical milestones, such as completion of enrollment in the pivotal Phase 3 CYPRESS study of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), and regulatory approvals such as Viatris securing NMPA approval in China for YUPELRI.
Theravance Biopharma’s 8-K filings also document patent and litigation developments, including settlement agreements related to YUPELRI patents with generic manufacturers under the Hatch-Waxman Act. These filings outline licensed launch dates for potential generic versions and note that certain settlements are subject to review by U.S. competition authorities.
Through this filings page, users can access the company’s furnished exhibits, including press releases and investor slide decks referenced in Forms 8-K, to better understand how Theravance Biopharma describes its respiratory franchise, late-stage ampreloxetine program, and strategic review activities. Stock Titan’s platform adds AI-powered summaries that explain the key points of lengthy filings, highlight material disclosures, and help readers quickly identify items related to YUPELRI collaboration economics, ampreloxetine clinical progress, and other events that may be relevant when analyzing TBPH stock.
Theravance Biopharma insider report: Miller Aine, SVP, Development & Head of IRE Office and an officer of Theravance Biopharma (TBPH), had 6,989 ordinary shares withheld on 08/20/2025 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The withholding was executed with the issuer and was not an open-market sale. After the transaction, the reporting person beneficially owned 208,001 shares. The per-share price for the withheld shares is reported as $13.39. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, reported a transaction on Form 4. On 08/20/2025 he disposed of 9,762 ordinary shares at an average price of $13.39 per share. The filing states the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units; the withholding was executed with the issuer and was not an open-market sale. After the transaction he beneficially owned 374,306 shares (direct). The Form 4 is signed 08/22/2025.
Rhonda Farnum, Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma (TBPH), reported a Form 4 disclosing a routine share withholding on 08/20/2025 to satisfy tax obligations from the vesting of previously granted restricted stock units. The filing shows 9,096 ordinary shares were withheld at an effective price of $13.39 per share; no open-market sale occurred. After the withholding, Farnum beneficially owned 317,822 shares of TBPH. The Form 4 is filed individually and signed by an attorney-in-fact on behalf of the reporting person.
Theravance Biopharma, Inc. announced that its subsidiaries and partners Mylan Ireland Limited and Viatris Specialty L.P. have entered into a Settlement Agreement with Cipla Limited and Cipla USA, Inc. covering YUPELRI® (revefenacin) inhalation solution patents. The agreement resolves ongoing Hatch-Waxman patent litigation related to Cipla’s abbreviated new drug application for a generic YUPELRI® product in the United States.
Under the Settlement Agreement, Theravance and Mylan granted Cipla a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Cipla’s generic version of YUPELRI® in the United States on or after the Licensed Launch Date of April 23, 2039, subject to customary exceptions. The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and separate patent litigation remains pending against another ANDA filer, Mankind Pharma Ltd. and certain affiliates.
Theravance Biopharma reported a profitable second quarter driven by a large one-time gain from the sale of TRELEGY royalties. The company recognized a net gain of $75.137 million on the sale and reported net income of $54.835 million for the three months ended June 30, 2025. Total revenues were $26.195 million for the quarter, including $18.695 million from the Viatris collaboration and a $7.5 million China regulatory milestone recognized as licensing revenue.
Liquidity strengthened materially: cash, cash equivalents, and restricted cash rose to $282.8 million and total assets increased to $426.0 million. Total shareholders' equity was $224.8 million, reducing the accumulated deficit to $924.3 million. The company retains potential remaining milestone receipts from Royalty Pharma of up to $150.0 million and remains eligible for additional Viatris milestones and China-region royalties. Legal proceedings related to ANDA filings and patent litigation are ongoing, with several settlements announced but some cases still pending.
Theravance Biopharma notified investors that it has issued a press release and will hold a conference call presenting its financial results for the quarter ended June 30, 2025 and a business update.
The materials supporting the call are being furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck). The filing states these exhibits are furnished and not filed, which limits certain statutory liabilities associated with filed disclosures.
Theravance Biopharma (NASDAQ: TBPH) filed an 8-K disclosing that China’s NMPA approved YUPELRI (revefenacin), the first once-daily nebulized LAMA for COPD in China.
The decision triggers a $7.5 million one-time milestone payment from partner Viatris, expected in Q3 2025, and entitles Theravance to additional sales-based milestones and tiered royalties on Chinese net sales. Viatris will fund and manage all development and commercialization activities.
No other financial statements were furnished; the disclosure is limited to Item 8.01 and Exhibit 99.1.
Rick E. Winningham, CEO and Director of Theravance Biopharma, reported a significant insider transaction on June 23, 2025. The executive made a bona fide gift of 20,000 ordinary shares with no compensation received.
Following the transaction, Winningham's holdings include:
- 1,733,180 shares held directly
- 13,500 shares held as custodian
- 92,567 shares held in trust
The Form 4 filing indicates Winningham maintains substantial ownership in the company despite the gifted shares. The transaction was executed under regular conditions and was not part of a Rule 10b5-1 trading plan. The filing was completed through his attorney-in-fact, Brett A. Grimaud, on June 25, 2025.